Although it frequently appears in tuberous sclerosis—a condition more often associated with a mutation in the TSC2 tumor suppressor gene rather than TSC1, which aberrantly activates the mTOR pathway—LAM is commonly diagnosed in its sporadic form (S-LAM), primarily affecting the lungs [1]. This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.